Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Autor: Goodyear CS; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Patel A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Barnes E; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Willicombe M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK., Siebert S; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., de Silva TI; Department of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Sheffield, UK., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK., Lim SH; Centre for Cancer Immunology, University of Southampton, Southampton, UK., Bowden SJ; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Billingham L; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Richter A; Clinical Immunology Service, University of Birmingham, Edgbaston, Birmingham, UK., Carroll M; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK., Carr EJ; The Francis Crick Institute, London, UK., Beale R; The Francis Crick Institute, London, UK., Rea D; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Parry H; Department of Haematology, University Hospitals Birmingham NHS Foundations Trust, Birmingham, UK., Pirrie S; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Lim Z; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Satsangi J; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Dunachie SJ; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Cook G; National Institute for Health Research Leeds MIC, University of Leeds, Leeds, UK., Miller P; British Society of Blood and Marrow Transplantation and Cellular Therapy, Guy's Hospital, London, UK., Basu N; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Gilmour A; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Hodgkins AM; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Evans L; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Hughes A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., Longet S; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; Centre International de Recherche en Infectiologie, Team GIMAP (Saint-Etienne), Université Claude Bernard Lyon 1, Inserm, CNRS, Lyon, France., Meacham G; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Yong KL; Cancer Institute, Department of Haematology, University College London, London, UK., A'Hearne MJ; Department of Haematology, Leicester Royal Infirmary, Leicester, UK., Koh MBC; Infection and Immunity Clinical Academic Group, St George's, University of London and Department of Haematology, St George's Hospital NHS Foundation Trust, London, UK., Burns SO; Clinical Immunology, Royal Free Hospital, Hampstead, London, UK; Institute of Immunity and Transplantation, University College London, Hampstead, London, UK., Orchard K; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Paterson C; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., McIlroy G; Department of Haematology, University Hospitals Birmingham NHS Foundations Trust, Birmingham, UK., Murray SM; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Thomson T; Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK., Dimitriadis S; Nuffield Department of Medicine, University of Oxford, Oxford, UK., Goulston L; National Institute of Health Research, Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Miller S; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Keillor V; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Prendecki M; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK., Thomas D; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK., Kirkham A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK., McInnes IB; College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK., Kearns P; Cancer Research UK Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, UK; National Institute for Health Research, Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. Electronic address: p.r.kearns@bham.ac.uk.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2024 Jun; Vol. 6 (6), pp. e339-e351. Date of Electronic Publication: 2024 May 08.